Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 17/20 | 0.75 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932188 | 0.86 | TTK (1.00) | TTKLRRK2JAK2 | |
| SCHEMBL16295745 | 0.83 | TTK (0.74) | TTKLRRK2JAK2 | |
| SCHEMBL16295250 | 0.82 | TTK (0.54) | TTKLRRK2 | |
| SCHEMBL16295859 | 0.82 | TTK (0.60) | TTK | |
| SCHEMBL16296380 | 0.80 | TTK (0.61) | TTK | |
| SCHEMBL16296012 | 0.80 | TTK (0.69) | TTKJAK2 | |
| SCHEMBL16296013 | 0.79 | TTK (0.80) | TTKLRRK2JAK2 | |
| SCHEMBL16296295 | 0.77 | TTK (0.53) | TTKLRRK2 | |
| SCHEMBL16296043 | 0.77 | TTK (0.59) | TTK | |
| SCHEMBL1932638 | 0.77 | TTK (0.75) | TTKLRRK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | claimed |
| EP-3008061-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | claimed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | claimed |
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-21 | — | — | US | disclosed |
| EP-3008061-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198594-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207928-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER | BUB1B, PLK1, BRCA1 | TTK 98/4885LRRK2 718/4885JAK2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.